{"filings":[{"id":101080,"accession_number":"0001654954-26-000277","cik":1081938,"company_name":"CANNAPHARMARX, INC.","ticker":"CPMD","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Director Rick Orman resigns; CannaPharmaRX exports 250 kg to Israel, plans Q1 shipments and expansion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Director Rick Orman resigned from board effective Jan 8, 2026; no dispute with company.","Exported 250 kg (6 batches) to Israel in Q4; three additional shipments scheduled Q1 2026.","New high-THC strains (Black Candyland, Goat Gas, Caligrape, Lemon Margy, Sour Chillz, Mac & Cheese) for German medical market.","Plans to raise capital, build 4 cultivation rooms, drying room, and EU-GMP processing area in 2026.","British Columbia Securities Commission cease trade order revoked effective December 12, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2510455.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117428,"accession_number":"0001654954-25-014070","cik":1081938,"company_name":"CANNAPHARMARX, INC.","ticker":"CPMD","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CannaPharmaRX announces revocation of cease trade order by BC Securities Commission","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["BC Securities Commission revoked failure-to-file cease trade order effective December 12, 2025.","Company faces going concern uncertainty with working capital deficiency of $27,009,769 as of Sep 30, 2025.","Related party debt totals $10,762,898 with accrued interest of $3,248,127 as of Sep 30, 2025.","Plans to increase cannabis production at Cremona facility and apply for EU-GMP certification to expand in Germany and Israel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2510455.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117427,"accession_number":"0001654954-25-011655","cik":1081938,"company_name":"CANNAPHARMARX, INC.","ticker":"CPMD","form_type":"8-K","filed_at":"2025-10-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CannaPharmaRX enters debt repayment schedules with two key debtholders","summary_kind":"llm","event_type":"debt","confidence":"low","bullets":["Entered letter agreements with payment schedules for outstanding debts to A. Tal and Koze Investments.","Agreements aim to avoid additional defaults while retaining capital for operations and product delivery.","Previously referenced in Q2 2025 10-Q but actual schedules were omitted; this 8-K corrects that omission.","No specific principal, interest, or payment terms disclosed in the 8-K text; details in attached exhibits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2510455.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150579,"accession_number":"0001654954-25-005135","cik":1081938,"company_name":"CANNAPHARMARX, INC.","ticker":"CPMD","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CannaPharmaRX completes first Germany shipment; 4 shipments to Israel done in 2024-2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First Germany shipment in March 2025: 227.5 kg at avg. 1.94 CAD/gram; 4 Israel shipments totalling 664.4 kg through April 2025.","Avg. price per gram for Israel shipments rose from 1.20 CAD (first) to 1.90 CAD (fourth).","Company acted as intermediary for other Canadian growers on Israel orders (54.26 kg in third, 73.17 kg in fourth) – a new revenue stream.","Second Germany shipment planned for June 2025: ~241 kg, pricing 1.82-2.04 CAD/gram depending on THC content.","Currently cultivating 5 of 10 rooms; expects each room to yield 60-80 kg/month, total monthly sales >CAD$300,000 after expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2510455.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169537,"accession_number":"0001654954-25-003608","cik":1081938,"company_name":"CANNAPHARMARX, INC.","ticker":"CPMD","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CannaPharmaRX appoints Constantine Nkafu as interim CEO, adds two directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Constantine Nkafu appointed interim CEO and board member; has led operations for past several months.","Elliot Zemel appointed to board; holds Health Canada authorization for director role.","Adam Mindle was previously designated but decided not to pursue Health Canada approval, never became director.","Board now consists of Richard Orman, Dominic Colvin, Anthony Michael Panek, Nkafu, and Zemel.","Nkafu receives $97,000 annual salary through subsidiary employment agreement with 2323414 Alberta Ltd."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2510455.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186585,"accession_number":"0001654954-24-015107","cik":1081938,"company_name":"CANNAPHARMARX, INC.","ticker":"CPMD","form_type":"8-K","filed_at":"2024-12-03T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"CannaPharmaRX appoints Barzily & Co. as new independent auditor for FY 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Engaged Barzily & Co. as independent registered public accounting firm on November 29, 2024.","No prior consultations with Barzily on accounting principles, audit opinions, or financial reporting issues.","No disagreements or reportable events occurred between Company and Barzily during past two fiscal years.","Auditor change is for fiscal year ending December 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2510455.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186584,"accession_number":"0001654954-24-014753","cik":1081938,"company_name":"CANNAPHARMARX, INC.","ticker":"CPMD","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Auditor GreenGrowth CPAs resigns from CannaPharmaRX effective Nov 14, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["GreenGrowth CPAs resigned as auditor effective November 14, 2024.","No disagreements or reportable events during GreenGrowth's engagement since 2023.","FY2023 audit report included a going concern paragraph due to recurring losses and negative cash flows.","Company is seeking a new auditor; no replacement engaged as of filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2510455.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203155,"accession_number":"0001683168-24-006456","cik":1081938,"company_name":"CANNAPHARMARX, INC.","ticker":"CPMD","form_type":"8-K","filed_at":"2024-09-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CannaPharmaRX CEO Dean Medwid resigns for personal reasons; board searches for successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dean Medwid stepped down as CEO effective September 9, 2024, for personal reasons.","No disagreement between Medwid and the company on operations, policies, or practices.","Board of Directors has begun search for a replacement CEO.","In the interim, board will collectively manage day-to-day operations.","Company expects a smooth transition with minimal operational interruption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2510455.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239294,"accession_number":"0001683168-24-001108","cik":1081938,"company_name":"CANNAPHARMARX, INC.","ticker":"CPMD","form_type":"8-K/A","filed_at":"2024-02-22T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"CannaPharmaRX finalizes multi-million dollar supply agreement with Cantek for Israeli cannabis market","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with Cantek, Israeli medical cannabis distributor, for minimum 1,000 kgs of product annually.","Initial shipment expected late Q1 2024; all necessary export and import permits secured.","Direct access to Israel's growing medical cannabis market, bolstered by recent supportive legislation.","CEO Dean Medwid states the agreement validates pre-sold product strategy for each planting cycle."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2510455.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239295,"accession_number":"0001683168-24-001042","cik":1081938,"company_name":"CANNAPHARMARX, INC.","ticker":"CPMD","form_type":"8-K","filed_at":"2024-02-16T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"CannaPharmaRX enters supply agreement with Cantek for minimum 1,000 kg/year at $2.75 CDN/g","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cantek commits to minimum 1,000 kg of product annually for 3 years at $2.75 CDN/g.","Most-favored-nations clause ensures Cantek receives any better pricing offered to others.","Termination provisions include failure to pay and other standard breaches.","Supply Agreement term is 3 years with renewal options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2510455.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256808,"accession_number":"0001683168-23-008658","cik":1081938,"company_name":"CANNAPHARMARX, INC.","ticker":"CPMD","form_type":"8-K","filed_at":"2023-12-06T23:59:59+00:00","items":["1.01","2.01","3.02","9.01"],"status":"ready","headline":"CannaPharmaRX acquires LTB Management for 33% stake, $3M notes, and warrants","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired all Class B interests in LTB Management; total consideration includes convertible preferred stock representing 33% of fully-diluted common (adjustable 28%-45% based on earn-out).","Issued warrants to purchase 27,224,962 shares at $0.02/share and $3,000,000 in 13% secured promissory notes.","Earn-out: if LTB annual revenue reaches $2.5M within 24 months, sellers' stake rises to 45%; if below, drops to 28%.","LTB develops cannabis e-commerce technology with AI catalog, featuring over 500 strains and 1.2M social media followers.","Sellers to introduce investors for up to $3M in additional capital; no change to purchase price based on success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2510455.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256807,"accession_number":"0001683168-23-007964","cik":1081938,"company_name":"CANNAPHARMARX, INC.","ticker":"CPMD","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"CannaPharmaRX terminates auditor BF Borgers, engages GreenGrowth CPAs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BF Borgers CPA PC terminated as independent auditor effective Nov 6, 2023; served since 2018.","No disagreements or reportable events in 2022, 2021, or interim 2023 period.","Prior audit reports included going-concern explanatory paragraph due to losses and negative cash flows.","GreenGrowth CPAs engaged Nov 3, 2023 as new auditor; decision approved by full Board.","No prior consultations with GreenGrowth on accounting principles or disagreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2510455.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256806,"accession_number":"0001683168-23-007145","cik":1081938,"company_name":"CANNAPHARMARX, INC.","ticker":"CPMD","form_type":"8-K","filed_at":"2023-10-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CannaPharmaRX appoints Oliver Foeste as CFO; John Cassels departs without disagreement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Cassels replaced as CFO effective Oct 13, 2023; no disagreement with company on operations.","Oliver Foeste appointed CFO; founder of Invictus Accounting Group, CPA, senior finance roles at TSX, TSXV, NYSE issuers.","Foeste engaged in July 2023 for backup CFO services; compensation includes annual bonuses/stock options and hourly billing $65-$400.","No family relationships or material interests between Foeste and any director/officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2510455.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274165,"accession_number":"0001683168-23-006113","cik":1081938,"company_name":"CANNAPHARMARX, INC.","ticker":"CPMD","form_type":"8-K","filed_at":"2023-08-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CannaPharmaRx expands board to five; Branson resigns, Panek and Mindle appointed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Branson resigned from board effective March 23, 2023, not due to any dispute.","Board expanded from three to five seats; Anthony Panek and Adam Mindle appointed August 15, 2023.","Panek is a corporate M&A attorney and venture capital investor with cannabis experience.","Mindle is a transactional attorney with extensive real estate, finance, and M&A experience.","Both Panek and Mindle have applied for Health Canada clearance to serve as directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2510455.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291364,"accession_number":"0001683168-23-004371","cik":1081938,"company_name":"CANNAPHARMARX, INC.","ticker":"CPMD","form_type":"8-K","filed_at":"2023-06-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CannaPharmaRX appoints Dean Medwid as CEO; Dominic Colvin steps down","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dominic Colvin stepped down as CEO effective June 1, 2023; no disagreement over operations.","Dean Medwid appointed CEO effective June 1, 2023; base salary of CDN $17,325/month plus bonus.","Medwid has 30+ years experience, previously President of New Leaf Ventures, a cannabis company.","Colvin will remain with the company providing 'leadership and vision.'","No family relationships or material interests between Medwid and other officers/directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2510455.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":384533,"accession_number":"0001683168-22-001069","cik":1081938,"company_name":"CANNAPHARMARX, INC.","ticker":"CPMD","form_type":"8-K","filed_at":"2022-02-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CannaPharmaRx signs LOI to acquire Oklahoma cannabis facility with $21M estimated annual revenue","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Signed LOI to purchase 35,000 sq ft operating cannabis facility in Braman, OK; planned expansion to 65,000 sq ft by end of 2022.","Acquisition via secured note; expected closing before March 31, 2022; includes license transfer.","Facility estimated to generate ~$21M annual revenue; combined with Cremona facility projects $40-50M revenue.","Oral offtake commitments obtained; CEO expects significant revenue recognition in early Q2."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2510455.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":421337,"accession_number":"0001683168-21-002989","cik":1081938,"company_name":"CANNAPHARMARX, INC.","ticker":"CPMD","form_type":"8-K","filed_at":"2021-07-16T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"CannaPharmaRx sells Hanover facility for $2M CAD to reduce debt","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold Hanover, Ontario facility for $2,000,000 CAD, including 10 acres and 48,800 sq ft of growing space.","Sale unanimously approved by senior management; proceeds to eliminate debt and liabilities.","CEO Nick Colvin states sale will 'vastly improve the bottom line of our balance sheet'.","Company cites focus on more technologically advanced facilities as reason for divestiture."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2510455.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}